Alpha Tau Medical Ltd. (DRTS)
NASDAQ: DRTS · Real-Time Price · USD
2.450
-0.060 (-2.39%)
Apr 1, 2025, 3:51 PM EDT - Market open
Alpha Tau Medical Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Alpha Tau Medical stock have an average target of 8.00, with a low estimate of 7.00 and a high estimate of 9.00. The average target predicts an increase of 226.53% from the current stock price of 2.45.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Alpha Tau Medical stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +267.35% | Mar 17, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +267.35% | Nov 22, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +267.35% | Oct 23, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +267.35% | Oct 11, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +267.35% | Aug 20, 2024 |
Financial Forecast
Revenue This Year
n/a
from 262.32M
Revenue Next Year
n/a
EPS This Year
-0.52
from -0.45
EPS Next Year
-0.36
from -0.52
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 1.4M | 41.1M | 45.1M | ||
Avg | 441,997 | 25.0M | 29.9M | ||
Low | n/a | 9.6M | 15.4M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -99.5% | 9,200.1% | 80.5% | ||
Avg | -99.8% | 5,552.5% | 19.8% | ||
Low | - | 2,081.7% | -38.4% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -0.51 | -0.06 | -0.35 | ||
Avg | -0.52 | -0.36 | -0.37 | ||
Low | -0.52 | -0.49 | -0.39 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.